Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | PPIA | P62937 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312502 | 1.00 | KMT2A (0.75) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL11326938 | 0.90 | KMT2A (0.85) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL7600834 | 0.88 | ALDH1A1 (0.72) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL30483195 | 0.88 | ALDH1A1 (0.72) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL5530308 | 0.87 | KMT2A (0.67) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL1504555 | 0.86 | MEN1 (1.00) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL10889357 | 0.85 | KMT2A (0.65) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL10005082 | 0.85 | MAPT (0.74) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL29502906 | 0.85 | MAPT (0.74) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL10937894 | 0.84 | RAB9A (0.64) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2528925-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | Hanmi Science Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011093684-A2 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI HOLDINGS CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| CN-101415689-A | Substituted quinazolines with anti-cancer activity | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | CN | disclosed |
| EP-2007736-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2007113557-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1828147-A1 | QUINOXALINES AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| CN-101001845-A | Substituted quinazolones as anti-cancer agents. | ASTRAZENECA AB (SE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | KMT2A 2503/4885MAPT 4337/4885MEN1 1111/4885 |
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | KMT2A 2857/4885MAPT 4484/4885MEN1 872/4885 |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | BRAF, NRAS, RAF1 | KMT2A 2579/4885MAPT 4546/4885MEN1 675/4885 |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | KMT2A 1967/4885MAPT 4559/4885MEN1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.